$NUVL $500M upsized offering priced at $100/share.

$MRK Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in PFS Vs. Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC in HERTHENA-Lung02 Phase 3 Trial. businesswire.com/news/home/2024…

$VIGL FDA Has Removed Partial Clinical Hold on VG-3927

$ADMA to Join S&P SmallCap 600 Index

Court Finds $UTHR Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million. $LQDA liquidia.com/news-releases/…

Ozempic ‘Very Likely’ Target for Next US Price Cut - $NVO The diabetes drug likely to see a reduction in 2027 $LLY $VKTX bnnbloomberg.ca/business/compa…

$PPBT Reports Additional Positive Interim Data from Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24. purple-biotech.com/press-viewer/?…

$MRK FDA Approves Merck’s KEYTRUDA Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Baird - BUY weakness $MREO PT 8 Remain positive despite recent weakness in shares surrounding competitor update. BOOST Pharma announced top-line results small Phase1/2 study of an allogeneic cell therapy in OI yesterday premarket, which we believe may have attributed to weakness

$COR Cencora Paid Hackers Largest Known Ransom of $75 Million. bloomberg.com/news/articles/…

$EWTX Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) businesswire.com/news/home/2024…

$ACHL to discontinue development of TIL-based cNeT therapy. Cash position of $95M.

$BTAI to prioritize clinical programs for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s disease - while deprioritizing sales efforts for its approved drug IGALMI sublingual film.

$ALGS Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH investor.aligos.com/news-releases/…

$LBPH Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

$RSLS 1-for-58 reverse split.

🔥 Hottest #ESMO24 Tweets Recap 📝 𝕏 Interesting posts/ppl to check out! 👀 👇 Drugs $ACRV decided to simply 𝘯𝘰𝘵 𝘴𝘩𝘰𝘸 the ovarian cancer patients » x.com/drug_smolecule… Jonathan Faison $ACRV (L) Early ESMO winner to my eyes » x.com/jfais20/status…

$ASND $281M offering priced at $150/ADS